Blog
RSS FeedPosted by Michael Wonder on 30 Nov 2023
Prevalence and nature of manufacturer-sponsored patient support programs for prescription drugs in Canada: a cross-sectional study
27 November 2023 - Of the 2556 prescription drugs marketed by 89 companies in the study period, 256 (10.0%) had a ...
Posted by Michael Wonder on 20 Nov 2023
Landmark medicines deal to boost nation’s health, save NHS £14 billion, and support research investment
20 November 2023 - Pro-innovation and pro-competition agreement will introduce a new mechanism to support lower industry payment rates for more ...
Posted by Michael Wonder on 13 Apr 2023
‘A global outlier’: how drug firms are fighting back against UK tax increases
13 April 2023 - With the UK tax on net sales of branded medicines quadrupling over the past three years, medicine ...
Posted by Michael Wonder on 03 Mar 2023
Health minister disputes claim he sided with big pharma, interfered with drug price consultations
1 March 2023 - Review board 'will never be subjected to political interference,' Duclos said. ...
Posted by Michael Wonder on 01 Mar 2023
ABPI sets out new proposals to support the NHS and economic growth
1 March 2023 - The pharmaceutical industry’s offer includes an annual £1 billion boost to the NHS as well as an ...
Posted by Michael Wonder on 17 Feb 2023
High drug prices are not justified by industry’s spending on research and development
15 February 2023 - Aris Angelis and colleagues argue that by refocusing their spending drug companies could provide more innovative ...
Posted by Michael Wonder on 07 Feb 2023
The EU butts heads with big pharma to make medicines cheaper
2 February 2023 - The bloc’s pharma reform aims to get new drugs to patients faster, for less money. But it ...
Posted by Michael Wonder on 06 Feb 2023
Pharma industry urges halt to further rises in record revenue clawbacks
2 February 2023 - The pharmaceutical industry is calling on the government to scrap plans to raise the statutory revenue clawback ...
Posted by Michael Wonder on 19 Jan 2023
The battle over European drug pricing
19 January 2023 - UK and EU must balance health cost control with plans to grow life sciences. ...
Posted by Michael Wonder on 17 Jan 2023
Innovative Medicines Canada proposes framework for innovative agreements for drug reimbursement
16 January 2023 - Pharmaceutical manufacturers in Canada often enter into product listing agreements, particularly with public payers, to facilitate their ...
Posted by Michael Wonder on 17 Jan 2023
Bayer shifts pharma focus away from ‘innovation unfriendly’ Europe
16 January 2023 - Bayer has said it is shifting the focus of its pharmaceutical business to the US and ...
Posted by Michael Wonder on 16 Jan 2023
AbbVie and Eli Lilly, two of the world’s largest pharmaceutical companies, have sent a warning signal to the UK government by leaving the voluntary medicines pricing agreement in protest over increasingly punitive revenue clawbacks
16 January 2023 - AbbVie and Lilly have left the UK’s Voluntary Scheme for Branded Medicines Pricing and Access, a ...
Posted by Michael Wonder on 20 Oct 2022
New Zealand, it's time to put Fairness in Focus
20 October 2022 - Medicines New Zealand is today relaunching their digital public awareness platform Fairness in Focus. ...
Posted by Michael Wonder on 30 Jun 2022
New strategic agreements with the medicines industry – PBS website updates
1 July 2022 - Amendments made by the National Health Amendment (Enhancing the Pharmaceutical Benefits Scheme) Act 2021 give effect to ...
Posted by Michael Wonder on 19 Apr 2022
Supply related data in manufacturer dossiers: things are not going smoothly yet
19 April 2022 - The criteria for supply related data established by IQWiG in 2020 were positively received in science. ...